- Orthocell has appointed experienced medical technology (medtech) executive,Leslie Wise, JD, as Executive Director
- Leslie has more than 20 years of specialist experience working in US reimbursement, life science, and medtech fields, and is ideally suited to support the next phase of Orthocell’s development
- With a leading regenerative medicine portfolio and experienced senior adviorsy team, Orthocell is ideally positioned to drive its products into the US, EU, and AUS markets
Perth, Australia; 10 June 2020: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the Company”) is pleased to announce the appointment of Leslie Wise, JD, as Executive Director.
Orthocell Managing Director, Paul Anderson, said: “We are delighted to welcome Leslie to the Orthocell Board. Leslie has extensive experience in securing US market access and reimbursement for medical devices as well as serving in various senior management positions across large US medical device and pharmaceutical companies. Leslie’s depth of knowledge and expertise is ideally suited to our product range and the next phase of growth for Orthocell.”